To hear about similar clinical trials, please enter your email below
Trial Title:
Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
NCT ID:
NCT05755295
Condition:
Neuroblastoma
Conditions: Official terms:
Neuroblastoma
Medulloblastoma
Conditions: Keywords:
hippotherapy
equitherapy
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
horse therapy
Description:
equitherapy and hippotherapy once a week during 16 weeks
Arm group label:
horse therapy
Summary:
On average, each year in the former region, 60 new patients under the age of 18 are
treated for a brain tumor, with an active post-treatment follow-up file of 350 patients.
Because of the significant sequelae induced by the disease or the treatments, these
patients will very often require rehabilitative care.
The interest of involving the horse in the population of patients cured of a
medulloblastoma but with important physical and psychological after-effects is to be able
to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy
based on the three-dimensional movement of the horse (hippotherapy).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- complete remission of medulloblastoma and after 5 years of the end of treatment
- living within 30 km away the riding center and/or less than 1 hour of transport
- informed consent
Exclusion Criteria:
- Landsky score below 50% for minors until 16 years old and Karnofsky score below 50%
for patients over 16 years
- major under juridical protection
Gender:
All
Minimum age:
10 Years
Maximum age:
26 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
CHU de Toulouse
Address:
City:
Toulouse
Zip:
31059
Country:
France
Status:
Recruiting
Contact:
Last name:
Anne-Isabelle BERTOZZI, MD
Phone:
0561772233
Email:
bertozzi.ai@chu-toulouse.fr
Start date:
April 3, 2023
Completion date:
March 1, 2026
Lead sponsor:
Agency:
University Hospital, Toulouse
Agency class:
Other
Source:
University Hospital, Toulouse
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05755295
